Imaging of glutamate neurotransmitter alterations in Alzheimer's disease

Mohammad Haris, Kavindra Nath, Kejia Cai, Anup Singh, Rachelle Crescenzi, Feliks Kogan, Gaurav Verma, Sanjana Reddy, Hari Hariharan, Elias R. Melhem, Ravinder Reddy

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP-PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild-type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the brain. The change in [Glu] was further validated through 1H MRS. A positive correlation was observed between GluCEST contrast and 1H MRS-measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease-modifying therapies for AD.

Original languageEnglish
Pages (from-to)386-391
Number of pages6
JournalNMR in Biomedicine
Volume26
Issue number4
DOIs
Publication statusPublished - Apr 2013
Externally publishedYes

Fingerprint

Neurotransmitter Agents
Glutamic Acid
Alzheimer Disease
Imaging techniques
Amines
Brain
Disease control
Creatine
Biomarkers
Transgenic Mice

Keywords

  • Alzheimer's disease
  • Brain
  • Chemical exchange saturation transfer imaging
  • Glutamate
  • MRI
  • MRS

ASJC Scopus subject areas

  • Spectroscopy
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Haris, M., Nath, K., Cai, K., Singh, A., Crescenzi, R., Kogan, F., ... Reddy, R. (2013). Imaging of glutamate neurotransmitter alterations in Alzheimer's disease. NMR in Biomedicine, 26(4), 386-391. https://doi.org/10.1002/nbm.2875

Imaging of glutamate neurotransmitter alterations in Alzheimer's disease. / Haris, Mohammad; Nath, Kavindra; Cai, Kejia; Singh, Anup; Crescenzi, Rachelle; Kogan, Feliks; Verma, Gaurav; Reddy, Sanjana; Hariharan, Hari; Melhem, Elias R.; Reddy, Ravinder.

In: NMR in Biomedicine, Vol. 26, No. 4, 04.2013, p. 386-391.

Research output: Contribution to journalArticle

Haris, M, Nath, K, Cai, K, Singh, A, Crescenzi, R, Kogan, F, Verma, G, Reddy, S, Hariharan, H, Melhem, ER & Reddy, R 2013, 'Imaging of glutamate neurotransmitter alterations in Alzheimer's disease', NMR in Biomedicine, vol. 26, no. 4, pp. 386-391. https://doi.org/10.1002/nbm.2875
Haris, Mohammad ; Nath, Kavindra ; Cai, Kejia ; Singh, Anup ; Crescenzi, Rachelle ; Kogan, Feliks ; Verma, Gaurav ; Reddy, Sanjana ; Hariharan, Hari ; Melhem, Elias R. ; Reddy, Ravinder. / Imaging of glutamate neurotransmitter alterations in Alzheimer's disease. In: NMR in Biomedicine. 2013 ; Vol. 26, No. 4. pp. 386-391.
@article{050420335ef846cab479b4c8ee2fe600,
title = "Imaging of glutamate neurotransmitter alterations in Alzheimer's disease",
abstract = "Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP-PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild-type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30{\%}) in all areas of the brain. The change in [Glu] was further validated through 1H MRS. A positive correlation was observed between GluCEST contrast and 1H MRS-measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease-modifying therapies for AD.",
keywords = "Alzheimer's disease, Brain, Chemical exchange saturation transfer imaging, Glutamate, MRI, MRS",
author = "Mohammad Haris and Kavindra Nath and Kejia Cai and Anup Singh and Rachelle Crescenzi and Feliks Kogan and Gaurav Verma and Sanjana Reddy and Hari Hariharan and Melhem, {Elias R.} and Ravinder Reddy",
year = "2013",
month = "4",
doi = "10.1002/nbm.2875",
language = "English",
volume = "26",
pages = "386--391",
journal = "NMR in Biomedicine",
issn = "0952-3480",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Imaging of glutamate neurotransmitter alterations in Alzheimer's disease

AU - Haris, Mohammad

AU - Nath, Kavindra

AU - Cai, Kejia

AU - Singh, Anup

AU - Crescenzi, Rachelle

AU - Kogan, Feliks

AU - Verma, Gaurav

AU - Reddy, Sanjana

AU - Hariharan, Hari

AU - Melhem, Elias R.

AU - Reddy, Ravinder

PY - 2013/4

Y1 - 2013/4

N2 - Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP-PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild-type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the brain. The change in [Glu] was further validated through 1H MRS. A positive correlation was observed between GluCEST contrast and 1H MRS-measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease-modifying therapies for AD.

AB - Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP-PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild-type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the brain. The change in [Glu] was further validated through 1H MRS. A positive correlation was observed between GluCEST contrast and 1H MRS-measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease-modifying therapies for AD.

KW - Alzheimer's disease

KW - Brain

KW - Chemical exchange saturation transfer imaging

KW - Glutamate

KW - MRI

KW - MRS

UR - http://www.scopus.com/inward/record.url?scp=84875055222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875055222&partnerID=8YFLogxK

U2 - 10.1002/nbm.2875

DO - 10.1002/nbm.2875

M3 - Article

C2 - 23045158

AN - SCOPUS:84875055222

VL - 26

SP - 386

EP - 391

JO - NMR in Biomedicine

JF - NMR in Biomedicine

SN - 0952-3480

IS - 4

ER -